# Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b

**Authors:** Elisabetta Vergani, Lorenza Di Guardo, Matteo Dugo, Sara Rigoletto, Gabrina Tragni, Roberta Ruggeri, Federica Perrone, Elena Tamborini, Annunziata Gloghini, Flavio Arienti, Barbara Vergani, Paola Deho, Loris De Cecco, Viviana Vallacchi, Paola Frati, Eriomina Shahaj, Antonello Villa, Mario Santinami, Filippo De Braud, Licia Rivoltini, Monica Rodolfo

PMC · DOI: 10.18632/oncotarget.28746 · Oncotarget · 2025-06-10

## Full-text entities

- **Genes:** CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, MIR100 (microRNA 100) [NCBI Gene 406892] {aka MIRN100, miR-100}
- **Diseases:** melanoma (MESH:D008545)
- **Chemicals:** vemurafenib (MESH:D000077484)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12151401/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12151401/full.md

---
Source: https://tomesphere.com/paper/PMC12151401